Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis

The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dailong, Li, Wanqiang, Tian, Cheng, Pang, Yaqi, Xu, Lu, Wang, Yuke, Xu, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524916/
https://www.ncbi.nlm.nih.gov/pubmed/36181032
http://dx.doi.org/10.1097/MD.0000000000030815
Descripción
Sumario:The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the expression of nm23-H1 and clinicopathological features in patients with NSCLC. METHODS: Literature search in PubMed, EMBASE, Cochrane Library, CNKI, and WanFang database was performed up to June 14, 2021. Studies on the expression and clinical significance of nm23-H1 in NSCLC were included. According to the inclusion and exclusion criteria, 2 researchers independently screened the literatures, extracted the data, and evaluated the quality. Meta-analysis was performed using RevMan 5.4 software (Nordic Cochran Centre, Copenhagen, Denmark). RESULTS: Twenty-five studies met our inclusion criteria and were finally included for the analysis, involving 2198 participants. Our meta-analysis revealed that nm23-H1 expression was associated with tumor differentiation (OR = 0.54, 95% CI: 0.42–0.70, P < .00001), TNM stage (OR = 1.70, 95% CI: 1.23–2.34, P = .001), and lymph node status (OR = 0.26, 95% CI, 0.17–0.39, P < .00001), but have no associate with sex, age, pathological type, and T stages. Additionally, low nm23-H1 expression reduced the 3-year survival rate (OR = 2.74, 95% CI: 1.54–4.86, P = .0006) and 5-year survival rate (OR = 2.78, 95% CI: 1.36–5.69, P = .005). CONCLUSION: Nm23-H1 can be used as a biomarker to predict tumor invasiveness and evaluate the prognosis of patients with NSCLC.